blood based shield test (Guardant Health)
86
Structured Review
Guardant Health
blood based shield test
Blood Based Shield Test, supplied by Guardant Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shield+test/guardant+health+launched+shield/pm41266596-249-3-6
Average 86 stars, based on 1 article reviews
Blood Based Shield Test, supplied by Guardant Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shield+test/guardant+health+launched+shield/pm41266596-249-3-6
Average 86 stars, based on 1 article reviews
blood based shield test - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Derivative Assay:Article Title: Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies Article Snippet: .. CRC screening test sensitivity and specificity inputs were derived from recent clinical trials: BLUE-C ( NCT04144738 ) for next-generation multitarget stool DNA (Cologuard Plus TM , Exact Sciences Corporation, Madison, WI, USA) and fecal immunochemical test (OC-Auto Micro 80 iFOB Test, Polymedco, LLC, Cortlandt Manor, NY, USA), CRC-PREVENT ( NCT04739722 ) for multitarget stool RNA (ColoSense TM , Geneoscopy, Inc., St Louis, MO, USA), Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE; NCT04136002 ) for the Clinical Proteomics:Article Title: Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies Article Snippet: .. CRC screening test sensitivity and specificity inputs were derived from recent clinical trials: BLUE-C ( NCT04144738 ) for next-generation multitarget stool DNA (Cologuard Plus TM , Exact Sciences Corporation, Madison, WI, USA) and fecal immunochemical test (OC-Auto Micro 80 iFOB Test, Polymedco, LLC, Cortlandt Manor, NY, USA), CRC-PREVENT ( NCT04739722 ) for multitarget stool RNA (ColoSense TM , Geneoscopy, Inc., St Louis, MO, USA), Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE; NCT04136002 ) for the other:Article Title: Article Snippet: For instance, in May 2022, Article Title: Article Snippet: For instance, in May 2022, Article Title: Article Snippet: For instance, in May 2022, Article Title: Implementation of blood-based colorectal cancer screening: real-world adherence and outcomes. Article Snippet: Objective: The overall CRC screening adherence rate remains suboptimal, with only 58% of screen-eligible individuals in the United States up to date with screening.. This analysis reports on real-world adherence, test outcomes, and turnaround times for the initial large-scale clinical implementation of a blood-based CRC screening test.. Methods: Providers ordered the commercially-available, blood-based Shield laboratory developed test (Guardant Health) in their clinics, based on an intended use population of individuals at average risk for CRC, aged 45 years or older. Biomarker Discovery:Article Title: From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies Article Snippet: .. For example, the Article Title: From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies. Article Snippet: .. For example, the Next-Generation Sequencing:Article Title: From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies Article Snippet: .. For example, the Article Title: From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies. Article Snippet: .. For example, the DNA Methylation Assay:Article Title: From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies Article Snippet: .. For example, the Article Title: From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies. Article Snippet: .. For example, the |